TYK2 mediates neuroinflammation in Alzheimer’s disease brains with TDP-43 pathology
Abstract
Abstract Neuroinflammation is a pathological feature of neurodegenerative diseases like Alzheimer’s disease and ALS. Cytoplasmic dsRNA (cdsRNA) triggers a type-I interferon response in human neural cells, leading to their death, and is found in neurons of C9ORF72 -ALS patients. Here, we report the spatial coincidence of cdsRNA and pTDP-43 inclusions in human postmortem tissue with Alzheimer’s disease pathology, and upregulated interferon response genes in affected regions. CdsRNA also accumulates in a human TDP-43 G298S iPSC cortical neuronal model. We use cryptic exon detection as a proxy for TDP-43 mislocalization and demonstrate that FDA-approved JAK inhibitors baricitinib and ruxolitinib, which block interferon signaling, show protective effects only in brains with elevated cryptic exon expression. A CRISPR screen reveals TYK2 as a top hit, and TYK2 knockdown and the selective TYK2 inhibitor deucravacitinib rescue cdsRNA-induced toxicity. We find parallel neuroinflammatory mechanisms, dependent on TYK2 - a potential disease-modifying target - for TDP-43-associated Alzheimer’s disease and C9ORF72 -ALS.
Article Details
Authors (25)
Laura E. König
Steve Rodriguez
Clemens Hug
Shayda Daneshvari
Alexander Chung
Mark Appleman
Max Tsai
Gary A. Bradshaw
Asli Sahin
Yuyu Song
George Zhou
Robyn J. Eisert
Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School
Federica Piccioni
Christine Marques
Sharon Powley
James Yarmolinsky
Brian J. Wainger
Sudeshna Das
Marian Kalocsay
Abbas Dehghan
Ioanna Tzoulaki
Artem Sokolov
Peter Sorger
David E. Root
Mark W. Albers
Department of Neurology, Harvard Medical School